About Verantos
Verantos is a Healthcare company based in Menlo Park (United States) founded in 2009. Data validation and regulatory services are provided to biopharma. The company has 29 employees. Its chief executive, as recorded, is Dan Riskin. Its Indian entity Verantos India Private Limited reported revenue of ₹11.44 Cr. Verantos offers products and services including Pragmatic Registry Platform and Research Network. Its focus areas include Biopharma Outsourcing, Consulting, Diversified and Services for Healthcare Providers. Its competitors include Indegene, Centivo and iMedX; 3 of its 3 listed competitors have raised funding.
Company details
Verantos was founded in 2009 and is based in Menlo Park, United States. Services focused on data validation and regulatory compliance are delivered to the biopharma sector. Operations involve ensuring data integrity and adherence to industry standards for pharmaceutical and biotechnology firms. Leadership is provided by CEO Dan Riskin, with activities centered on supporting validation processes across the sector.
- Headquarters Menlo Park, United States
- Employees 29
- SectorsHealthcare
- Website verantos.com
- Social LinkedIn X
- Legal Name Verantos India Private Limited
- Date of Incorporation 12 Sep, 2019
- Jurisdiction Pune, Maharashtra, India
- Indian entity revenue₹11.44 Cr
FY 2025 · +12% YoY
- Indian entity net profit₹1.20 Cr
FY 2025 · 10% margin
- Indian entity EBITDA₹1.73 Cr
FY 2025 · 15% margin
- Latest Funding Round$1.5M (USD), Grant
Jun 2018
- InvestorsNIH
& 1 more
- Employee Count29
Associated legal entities of Verantos
Verantos operates through Verantos India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Verantos India Private Limited CIN U72900PN2019FTC186621 | Active | 12 Sep 2019 | Pune, Maharashtra | ₹11.4 Cr | 29 | 3 | View details |
Products & Services of Verantos
Verantos offers a comprehensive portfolio of products and services, including Pragmatic Registry Platform and Research Network.
Generates disease-specific registries from real-world data for evidence.
Facilitates research and evidence sharing in life sciences domains.
Funding Insights of Verantos
- Total Rounds 1
- Last Round Grant — $1.5M
- First Round $1.5M
(Jun 2018)
- Investors Count 2
All 1 funding rounds of Verantos with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2018 | $1.5M | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Verantos
Verantos has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include NIH and National Science Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
A government-backed foundation providing seed-stage investments to support small businesses. | 1950 | nsf.gov | Arlington, United States |
Investor details for Verantos
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Verantos India Private Limited (Verantos)
Verantos India Private Limited is the primary company behind Verantos. The board of Verantos India Private Limited currently have 3 directors; the longest-serving is Jonathan Alexander Rovirosa, appointed in 2022. 6 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Jonathan Alexander Rovirosa DIN 09500444 | Director | 14 Feb 2022 | 4 yrs 8 mo | Verantos India Private Limited |
| Vivek Shende DIN 09842582 | Director | 09 Jan 2023 | 3 yrs 10 mo | Verantos India Private Limited |
| Padmanabha Niranjan Vedam DIN 09850919 | Director | 09 Jan 2023 | 3 yrs 10 mo | Verantos India Private Limited |
People of Verantos
24 people are tracked at Verantos (7 in leadership, 17 in team); the tracked headcount is 29.
| Name | Role | Group |
|---|---|---|
Dan Riskin | CEO | Leadership |
Dan West | VP, Marketing | Leadership |
Erin Murray | Director, RWE Program Management | Leadership |
Anand Shroff | President | Leadership |
Chet Kumar | VP, Life Sciences | Leadership |
| Vice President - Engineering, And India Head At Verantos | Leadership | |
Tim Wolfe | Vice President Of Product Management | Leadership |
Divyanshu Sankhwar | Senior Software Engineer | Team |
Nirmal Dawna | Human Resources Manager | Team |
Neha Wani | Clinical Annotator | Team |
Praveena Nair | Senior Program Manager | Team |
Anagha Konnur | Compliance Manager | Team |
Latif Shaikh | Software Engineer, Devops | Team |
Barry Richardson | Senior Product Designer | Team |
Jonathan Rovirosa CPA | Controller | Team |
Chris May | Technical Lead | Team |
Chetan Chavhan | Cloud Operations Engineer | Team |
Ryan Roper | Senior Software Engineer | Team |
Nicholas J | Principal Software Engineer | Team |
Smit Agrawal | Senior Engineering Manager | Team |
4 more people are available in the full profile.
Complete people profiles for Verantos
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Verantos
Figures of Verantos India Private Limited, the primary company behind Verantos, for FY 2025. Revenue was ₹11.44 Cr (+12% year on year). Net profit was ₹1.20 Cr (10% margin). EBITDA was ₹1.73 Cr (15% margin). Revenue has grown at a compounded annual rate of +32% over three years.
- ₹11.44 CrRevenue · FY 2025 · +12% YoY
- ₹1.20 CrNet profit · 10% margin
- ₹1.73 CrEBITDA · 15% margin
- ₹50 LakhPaid-up capital
- 29Employees (provident fund records)
- +32%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Verantos India Private Limited are on its company page.
Detailed financial statements for Verantos
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Verantos
2 dated milestones of Verantos across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Verantos is founded.
- Funding First funding round of $1.5M.
Competitors of Verantos
Verantos has 3 listed competitors in our database, 3 of them funded. They include Indegene, Centivo and iMedX.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| indegene.com | 1998 | Princeton, United States | $220M | 350 | Suite solutions are provided for payers and healthcare providers. | |
| centivo.com | 2017 | New York, United States | $224M | 212 | Provider of self funded health plan | |
| imedx.com | 2002 | Atlanta, United States | $22.28M | 951 | Revenue cycle management platform is provided to healthcare providers. |
Detailed competitors of Verantos
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Verantos (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Verantos
Complete news archive for Verantos
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Verantos
Verantos was founded in 2009 and raised its 1st funding round 9 years after it was founded.
Verantos is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Dan Riskin is the CEO of Verantos, as recorded in our data.
Verantos has 29 employees.
The primary company behind Verantos, Verantos India Private Limited, reported revenue of ₹11.44 Cr for FY 2025, up 12% year on year.
Verantos was founded in 2009 and is based in Menlo Park, United States. Services focused on data validation and regulatory compliance are delivered to the biopharma sector. Operations involve ensuring data integrity and adherence to industry standards for pharmaceutical and biotechnology firms. Leadership is provided by CEO Dan Riskin, with activities centered on supporting validation processes across the sector.
Verantos offers Pragmatic Registry Platform and Research Network.
Verantos has 2 investors. Key investors include NIH, and National Science Foundation.
Verantos operates through Verantos India Private Limited.
The legal entities of Verantos currently have 3 directors, including Vivek Shende, Jonathan Alexander Rovirosa, Padmanabha Niranjan Vedam.